संयुक्त राज्य - अंग्रेज़ी - NLM (National Library of Medicine)

preferred pharmaceuticals inc. - ipratropium bromide (unii: j697uz2a9j) (ipratropium - unii:gr88g0i6ul), albuterol sulfate (unii: 021sef3731) (albuterol - unii:qf8svz843e) - ipratropium bromide and albuterol sulfate inhalation solution is indicated for the treatment of bronchospasm associated with copd in patients requiring more than one bronchodilator. ipratropium bromide and albuterol sulfate inhalation solution is contraindicated in patients with a history of hypersensitivity to any of its components, or to atropine and its derivatives.

संयुक्त राज्य - अंग्रेज़ी - NLM (National Library of Medicine)

sun pharmaceutical industries, inc. - ipratropium bromide (unii: j697uz2a9j) (ipratropium - unii:gr88g0i6ul), albuterol sulfate (unii: 021sef3731) (albuterol - unii:qf8svz843e) - ipratropium bromide and albuterol sulfate inhalation solution is indicated for the treatment of bronchospasm associated with copd in patients requiring more than one bronchodilator. ipratropium bromide and albuterol sulfate inhalation solution is contraindicated in patients with a history of hypersensitivity to any of its components, or to atropine and its derivatives. ipratropium bromide (ih-pruh-troe-pee-uhm broe-mide) and albuterol sulfate (al-bue-ter-ol) inhalation  solution, usp 0.5 mg/3 mg *equivalent to 2.5 mg albuterol base read this patient information completely every time your prescription is filled as information may have changed. keep these instructions with your medication as you may want to read them again. ipratropium bromide and albuterol sulfate inhalation solution should only be used under the direction of a physician. your physician and pharmacist have more information about ipratropium bromide and albuterol sulfate inhalation solution and the condition for which it has been

संयुक्त राज्य - अंग्रेज़ी - NLM (National Library of Medicine)

remedyrepack inc. - ipratropium bromide (unii: j697uz2a9j) (ipratropium - unii:gr88g0i6ul), albuterol sulfate (unii: 021sef3731) (albuterol - unii:qf8svz843e) - ipratropium bromide and albuterol sulfate inhalation solution is indicated for the treatment of bronchospasm associated with copd in patients requiring more than one bronchodilator. ipratropium bromide and albuterol sulfate inhalation solution is contraindicated in patients with a history of hypersensitivity to any of its components, or to atropine and its derivatives. ipratropium bromide and albuterol sulfate inhalation solution 0.5 mg / 3 mg per 3 ml patient's instructions for use read this patient information completely every time your prescription is filled as information may have changed. keep these instructions with your medication as you may want to read them again. ipratropium bromide and albuterol sulfate inhalation solution should only be used under the direction of a physician. your physician and pharmacist have more information about ipratropium bromide and albuterol sulfate inhalation solution and the condition for which it has been prescribed. contact them if you have additional questions. stori

संयुक्त राज्य - अंग्रेज़ी - NLM (National Library of Medicine)

proficient rx lp - ipratropium bromide (unii: j697uz2a9j) (ipratropium - unii:gr88g0i6ul), albuterol sulfate (unii: 021sef3731) (albuterol - unii:qf8svz843e) - ipratropium bromide and albuterol sulfate inhalation solution is indicated for the treatment of bronchospasm associated with copd in patients requiring more than one bronchodilator. ipratropium bromide and albuterol sulfate inhalation solution is contraindicated in patients with a history of hypersensitivity to any of its components, or to atropine and its derivatives. ipratropium bromide (ih-pruh-troe-pee-uhm broe-mide) and albuterol sulfate (al-bue-ter-ol) inhalation  solution, usp 0.5 mg/3 mg *equivalent to 2.5 mg albuterol base read this patient information completely every time your prescription is filled as information may have changed. keep these instructions with your medication as you may want to read them again. ipratropium bromide and albuterol sulfate inhalation solution should only be used under the direction of a physician. your physician and pharmacist have more information about ipratropium bromide and albuterol sulfate inhalation solution and the condition for which it has been

संयुक्त राज्य - अंग्रेज़ी - NLM (National Library of Medicine)

physicians total care, inc. - ipratropium bromide (unii: j697uz2a9j) (ipratropium - unii:gr88g0i6ul) - ipratropium bromide 21 ug - atrovent nasal spray 0.03% is indicated for the symptomatic relief of rhinorrhea associated with allergic and nonallergic perennial rhinitis in adults and children age 6 years and older. atrovent nasal spray 0.03% does not relieve nasal congestion, sneezing, or postnasal drip associated with allergic or nonallergic perennial rhinitis. atrovent® (ipratropium bromide) nasal spray 0.03% is contraindicated in patients with a history of hypersensitivity to atropine or its derivatives, or to any of the other ingredients. atrovent® (ipratropium bromide) nasal spray 0.03% 21 mcg/spray read complete instructions carefully before using. in order to ensure proper dosing, do not attempt to change the size of the spray opening. atrovent nasal spray 0.03% is indicated for the symptomatic relief of rhinorrhea (runny nose) associated with allergic and nonallergic perennial rhinitis in adults and children age 6 years and older. atrovent nasal spray 0.03% does not relieve nasal congestion, sneezing, or postnasal drip asso

संयुक्त राज्य - अंग्रेज़ी - NLM (National Library of Medicine)

physicians total care, inc. - ipratropium bromide (unii: j697uz2a9j) (ipratropium bromide - unii:j697uz2a9j) - ipratropium bromide 17 ug - atrovent hfa inhalation aerosol is indicated as a bronchodilator for maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease, including chronic bronchitis and emphysema. atrovent hfa inhalation aerosol is contraindicated in patients with a history of hypersensitivity to ipratropium bromide or other atrovent hfa inhalation aerosol components. atrovent hfa inhalation aerosol is also contraindicated in patients who are hypersensitive to atropine or its derivatives. atrovent® hfa (ipratropium bromide hfa) inhalation aerosol read complete instructions carefully before using. important points to remember about using atrovent hfa inhalation aerosol    although atrovent hfa inhalation aerosol may taste and feel different    when breathed in compared to your atrovent® (ipratropium    bromide) inhalation aerosol cfc inhaler, they contain the same    medicine.    you do not have to shake the atrovent hfa inhalation aerosol canister    before using it.    atrovent hfa inhala

संयुक्त राज्य - अंग्रेज़ी - NLM (National Library of Medicine)

boehringer ingelheim pharmaceuticals, inc. - ipratropium bromide (unii: j697uz2a9j) (ipratropium - unii:gr88g0i6ul) - ipratropium bromide anhydrous 17 ug - atrovent hfa inhalation aerosol is indicated as a bronchodilator for maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (copd), including chronic bronchitis and emphysema. atrovent hfa is contraindicated in the following conditions [see warnings and precautions (5.2) ]. - hypersensitivity to ipratropium bromide or other atrovent hfa components - hypersensitivity to atropine or any of its derivatives risk summary ipratropium is negligibly absorbed systemically following oral inhalation; therefore, maternal use is not expected to result in fetal exposure to the drug [see clinical pharmacology (12.3)] . there is limited experience with ipratropium bromide use in pregnant women. published literature, including cohort studies, case control studies and case series, over several decades have not identified a drug associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. based on animal reproduction studies, no evidence of structural alteration

संयुक्त राज्य - अंग्रेज़ी - NLM (National Library of Medicine)

boehringer ingelheim pharmaceuticals inc. - ipratropium bromide (unii: j697uz2a9j) (ipratropium - unii:gr88g0i6ul), albuterol sulfate (unii: 021sef3731) (albuterol - unii:qf8svz843e) - ipratropium bromide anhydrous 20 ug - combivent respimat is a combination of ipratropium bromide (an anticholinergic agent) and albuterol sulfate (a beta2 -adrenergic agonist) indicated for use in patients with chronic obstructive pulmonary disease (copd) on a regular aerosol bronchodilator who continue to have evidence of bronchospasm and who require a second bronchodilator. combivent respimat is contraindicated in the following conditions [see warnings and precautions (5.6) ]: - hypersensitivity to any of the ingredients in combivent respimat - hypersensitivity to atropine or any of its derivatives risk summary there are no randomized clinical studies of combivent respimat, or its individual components, ipratropium bromide and albuterol sulfate, in pregnant women. ipratropium is negligibly absorbed systemically following oral inhalation; therefore, maternal use is not expected to result in fetal exposure to the drug [see clinical pharmacology (12.3)] . published literature, including cohort studies, case control studies and case series, over s

संयुक्त राज्य - अंग्रेज़ी - NLM (National Library of Medicine)

a-s medication solutions - ipratropium bromide (unii: j697uz2a9j) (ipratropium - unii:gr88g0i6ul) - ipratropium bromide inhalation solution administered either alone or with other bronchodilators, especially beta adrenergics, is indicated as a bronchodilator for maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease, including chronic bronchitis and emphysema. ipratropium bromide is contraindicated in known or suspected cases of hypersensitivity to ipratropium bromide, or to atropine and its derivatives. ipratropium bromide inhalation solution, 0.02% read complete instructions carefully before using. note: use only as directed by your physician. more frequent administration or higher doses are not recommended. ipratropium bromide inhalation solution can be mixed in the nebulizer with albuterol or metaproterenol if used within one hour but not with other drugs. drug stability and safety of ipratropium bromide inhalation solution when mixed with other drugs in the nebulizer have not been established. store between 59°f (15°c) and 86°f (30°). protect from light. store u

संयुक्त राज्य - अंग्रेज़ी - NLM (National Library of Medicine)

a-s medication solutions - ipratropium bromide (unii: j697uz2a9j) (ipratropium - unii:gr88g0i6ul) - ipratropium bromide nasal solution, 0.06% is indicated for the symptomatic relief of rhinorrhea associated with the common cold or seasonal allergic rhinitis for adults and children age 5 years and older. ipratropium bromide nasal solution, 0.06% does not relieve nasal congestion or sneezing associated with the common cold or seasonal allergic rhinitis. the safety and effectiveness of the use of ipratropium bromide nasal solution, 0.06% beyond four days in patients with the common cold or beyond three weeks in patients with seasonal allergic rhinitis has not been established. ipratropium bromide nasal solution, 0.06% is contraindicated in patients with a history of hypersensitivity to atropine or its derivatives, or to any of the other ingredients. ipratropium bromide nasal solution, 0.06% nasal spray (ip" ra troe' pee um broe' mide) rx only read complete instructions carefully before using. in order to ensure proper dosing, do not attempt to change the size of the spray opening. ipratropium bromide nasal so